Solid forms of an n-terminal domain androgen receptor inhibitor and uses thereof

Abstract

The present invention relates to a crystalline form of Compound I, a salt, a solvate, or a solvate salt thereof or an amorphous form of Compound I, a salt, a solvate, or a solvate salt thereof. The present invention also provides compositions comprising the crystalline form and/or the amorphous form, therapeutic uses of the crystalline forms and/or the amorphous forms, and the compositions thereof.

1 . A crystalline form of Compound I: 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt, solvate, or solvate salt thereof. 
     
     
         2 . The crystalline form of  claim 1 , wherein Compound I is anhydrous or non-solvated. 
     
     
         3 . The crystalline form of  claim 1 , wherein Compound I is not present as a pharmaceutically acceptable salt. 
     
     
         4 . The crystalline form of  claim 1  which exhibits an X-ray powder diffraction (XRPD) pattern comprising peaks at about 17.48±0.2, 20.78±0.2, and 21.80±0.2 degrees two-theta. 
     
     
         5 . The crystalline form of  claim 4 , wherein the XRPD pattern further comprises peaks at about 5.19±0.2 and 12.94±0.2 degrees two-theta. 
     
     
         6 . The crystalline form of  claim 4 , wherein the XRPD pattern further comprises at least two peaks selected from about 17.80±0.2, 18.74±0.2, 19.57±0.2, 22.59±0.2, 25.28±0.2, or 29.95±0.2 degrees two-theta. 
     
     
         7 . The crystalline form of  claim 4  which exhibits an XRPD pattern comprising peaks in Table 1B. 
     
     
         8 . (canceled) 
     
     
         9 . The crystalline form of  claim 1 , which is Form A exhibiting an XRPD pattern substantially similar to  FIG. 1 , provided that peaks at 27.3±0.2 and 31.7±0.2 degrees two-theta are excluded. 
     
     
         10 . The crystalline form of  claim 1  which exhibits a differential scanning calorimetry (DSC) thermogram comprising an endotherm peak which onset at about 182° C. 
     
     
         11 . The crystalline form of  claim 1  which exhibits a thermogravimetric analysis (TGA) thermogram comprising a change in slope which onset at about 284° C. 
     
     
         12 . The crystalline form of  claim 1 , wherein the crystalline form has a purity in the range of about 80% to about 99%. 
     
     
         13 . The crystalline form of  claim 1 , wherein the crystalline form has a purity of about 95% or higher. 
     
     
         14 . The crystalline form of  claim 1 , wherein the crystalline form has a purity of about 99% or higher. 
     
     
         15 .- 36 . (canceled) 
     
     
         37 . A composition comprising a crystalline form of  claim 1  and a pharmaceutically acceptable carrier. 
     
     
         38 . The composition of  claim 37 , wherein the crystalline form is Form A. 
     
     
         39 . The composition of  claim 37 , further comprising an amorphous form of Compound I or a pharmaceutically acceptable salt, solvate, or solvate salt thereof. 
     
     
         40 . (canceled) 
     
     
         41 . (canceled) 
     
     
         42 . The composition of  claim 37 , further comprising one or more additional therapeutic agents. 
     
     
         43 .- 52 . (canceled) 
     
     
         53 . A crystalline form of Compound I: 
       
         
           
           
               
               
           
         
       
     
     
         54 . A composition comprising a crystalline form of  claim 53  and a pharmaceutically acceptable carrier.